Product Description
Oprelvekin is a recombinant form of human interleukin 11, a cytokine that stimulates proliferation and maturation of bone marrow stem cells and megakaryocytes and is used to treat severe thrombocytopenia caused by chemotherapy. Interleukin 11 therapy has not been linked to serum enzyme elevations or with instances of jaundice or clinically significant acute liver injury. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/31643512/)
Mechanisms of Action: IL11 Agonist
Novel Mechanism: No
Modality: Coagulation Factor
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Brazil | Chile | China | Colombia | Peru | South Africa
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Pancytopenia|Thrombocytopenia
Phase 2: von Willebrand Diseases|Colorectal Cancer|Thrombocytopenia|Crohn Disease|Hemophilia A|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Chronic Myeloid Leukemia|Menorrhagia
Phase 1: Colitis, Ulcerative
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| IL-11xs | N/A |
Completed |
Thrombocytopenia|Thrombosis |
2022-05-16 |
|
| ChiCTR1800019725 | N/A |
Not yet recruiting |
Lymphoma |
2021-06-30 |
|
| FDRT-009 | P2 |
Unknown status |
Thrombocytopenia|Colorectal Cancer |
2019-09-01 |
|
| 3067K1-2213 | P2 |
Terminated |
Thrombocytopenia |
2015-12-01 |